Life Sciences Archive » October, 2015

Life Sciences - October, 2015

326 articles

• High Court Told 7th Circ. Was Too Easy On Class Cert. Bid
• Ex-BNY Manager Accused Of Insider Trading Seeks Probation
• Perrigo, Mylan Denied Competing Requests In $27B Bid Fight
• Pa. Court Won't Rethink Upholding $4M Topamax Verdict
• Patheon Defeats JV-Partner's Antitrust Suit Over Rival Buy
• Genentech Beats Avastin Off-Label Injury Claims In Texas
• Valeant Taps Kirkland & Ellis Atty As Pharmacy Crisis Grows
• Potential Pfizer-Allergan Deal Reignites Inversion Scrutiny
• Adderall Purchasers Push For Cert. In Pay-For-Delay Suit
• GNC Faces Shareholder Class Action After Ore. AG Suit
• Fresenius Beats FCA Suit Over Charging Free Excess Drugs
• Judge Bars Supplement Co. From False Ads In FTC Suit
• Merck Slams Discovery Bid In $250M Sex Bias Suit
• 9th Circ. Won't Rehear Oakland's Bid To Keep Pot Shop Open
• Theranos Scrutiny Shows FDA's Murky Oversight Of Lab Tests
• Court Rescinds Venable Sanction In Abbott Birth Defect Row
• The Latest Unsuccessful Inter Partes Review Petitions
• Claim Construction's Journey In The 9 Months Since Teva
• Genentech Dodges FCA Claims Over Avastin's Side Effects
• Venable Sanctioned For Trial Delay In Abbott Birth-Defect Suit
• Pharma Exec's Indictment Shows DOJ Not Bluffing
• How A Pfizer-Allergan Deal Would Rank Among 2015's Largest
• Walgreens Offers Rite Aid Up To $650M In Breakup Fees
• New Del. Law Can't Invalidate Genelux Stock, Court Says
• Taylor-Wharton Gets Nod For Quick Ch. 11 Auction
• Fed. Circ. Says Atlas WiFi Patent May Be Invalid
• Biotech Co. Claims Ex-Partner Stole Research For Chemo Drug
• Frazier Healthcare Closes $262M Life Sciences Fund
• Retailers Tell Court Not To DQ 12 Firms In Lidoderm MDL
• AstraZeneca Says Dr. Reddy's Heartburn Pill Can't Be Purple
• MyoKardia Raises $54M In Latest Discounted Biotech IPO
• Dow Must Pay $456M To Bayer In Plant Patent Row
• Calif. High Court Rejects Takeda Appeal Of $6M Actos Verdict
• Feds End Bristol-Myers FCPA Probe After $14M SEC Fine
• Myriad In Australia Vs. Myriad In The US
• Ex-Warner Chilcott Exec Charged In Kickback Scheme
• J&J Says Client-Attorney Friendship Dooms Sunscreen Action
• Allergan Confirms Deal Talks With Pfizer
• Novartis Snags Atty Fees From Webvention In Patent Fight
• 5 Law Firms That Inspire Fear With Their Marketing Mojo
• 7 Takeaways As Industries Clash Over 340B 'Mega-Guidance'
• Supplement Co. Can't Get Atty Sanctions In False Ad Suit
• Settlement Lessons From Key Players In Guidant MDL
• Zimmer Ruling Continues Pa. Justices' Pro-Plaintiff Trend
• The Firms Behind Walgreens' $17.2B Rite Aid Play
• Medical Device Co. Must Reinstate Chairman, Court Says
• Bargaining Power Key To Walgreens, Rite Aid Merger Review
• Zimmer Undoes Jury's 'Excessive' $9.2M Hip Implant Verdict
• FTC Says FDA Biosimilar Naming Rules May Confuse Doctors
• Boston Scientific Settles $34.5M Pelvic Mesh Suit In Texas
• PTAB Upholds ImmunoGen's Breast Cancer Drug Patent
• Insurer Rips Tyco For Delays In $60M Drug Heist Suit
• FDA Warns Novartis Over Violations At Indian Drug Plants
• TriReme Takes $20M Catheter IP Loss To Fed. Circ.
• Abbott, AbbVie Urge No Punitive Damages In Depakote Suit
• Dow And Teva: Indefiniteness Defense Can Be Powerful
• FDA Warning Wire: Theranos, Temperature Devices, Sutures
• P&G Gets Stay Of Probiotic Class For High Court Review
• All Eyes On DOJ As Novartis FCA Deal Takes Shape
• Pa. Justices Say $20M Zimmer Verdict Was Wrongly Voided
• Kyle Bass Group Gets PTAB To Review 2 Celgene Patents
• Taylor-Wharton Slams Objections To Its DIP Package
• Allergan Says Court Botched Facts In Botox Antitrust Suit
• Pro Bono: The New Associate's Compass To Success
• First Quality Wants Another Antitrust Shot In Diaper IP Row
• PTAB Again Denies Review Of Merck Anti-Nausea Drug
• Judge Refuses To Recuse Himself In Diet Pill Sanctions Row
• Shire Tells Fed Circuit It Erred In Generic Vyvanse Suit
• Novartis Inks $390M FCA Deal Over Pharmacy Discounts
• TPP Biologics Exclusivity Period Maintains The Status Quo
• Judge Orders Arrest Of Brothers In NuScience IP Row
• 6 New Developments In Valeant's Specialty Pharmacy Saga
• FDA Panel Backs AstraZeneca Gout Drug Amid Dosage Concerns
• DOJ Subpoenas Valeant Over Bausch & Lomb Payments
• 3rd Circ. Allows RICO Class Suit Against GSK Over Avandia
• Allergan Breast Implant Suit Can Be Amended, 9th Circ. Says
• Consumers Push For Dismissal In Eli Lilly Cymbalta Case
• Baxter Says Talks With Brokerage Firm Are Privileged
• Taylor-Wharton Unsecured Creditors Rip 'Egregious' DIP Loan
• Vitamin E User Says Calif. Rulings Keep CVS Suit Alive
• Kyle Bass-Backed Group Gets PTAB To Review Gattex Patent
• Viagra Increases Risk Of Developing Melanoma, Suit Says
• Proskauer Settles J&J Heir's Suit Claiming Faulty Tax Advice
• Risperdal Caused Autistic Boy's Breast Growth, Pa. Jury Told
• Zimmer Asks For Win In 1st Knee-Impant Bellwether Trial
• Biotech Co. Asks High Court To Enter Patent License Fray
• Refresh Or Rebuild? Website Strategies For Big Law
• Allegation Of Willful Infringement May Get Its Bite Back
• Justices Urged To Not Review Biolitec $70M Contempt Ruling
• EX-CFR Director Makes $13.2M Deal In Insider Trading Suit
• Spectrum To Confer With FDA On Cancer Drug Approval Delay
• Fired Bio-Rad GC Hangs On To Most Whistleblower Claims
• Pa. Judge Defends Barring Punitives At Risperdal Trials
• Are Patient Advisers Contraindicated For Pharma Cos.?
• Knee Implant Patient Testifies In 1st Zimmer Test Trial
• Mylan Argues IRS Can't Keep $100M Tax Dispute From Trial
• Shire Still Pushing For $30B Baxalta Deal
• Kansas City Fed Rejects Colorado Pot Credit Union
• Valeant Hit With Investor Suit Over Pharmacy Ties
• House Passes Bill To Repeal Key ACA Mandates
• Reining In FTC's Crusade Against Dietary Supplements
• Where We Stand On Pharmaceutical Patent Settlements
• Abbott Hits Back At Infant Formula False Ad Claims
• Calif. Marijuana Co. Owes Tax Under Federal Trafficking Law
• Zyprexa Liability Suit Belonged In State Court, 7th Circ. Says
• J&J Claims Prejudice Marred 1st Philly Risperdal Case
• FDA Adds Liver Safety Warning To AbbVie Hepatitis C Drugs
• Actos Buyers Head To 2nd Circ. After Pay-For-Delay Suit Nixed
• Fired Teva Atty Asks Court To Resuscitate Defamation Claim
• Adderall Buyers Defend Expert Report Deemed Late By Shire
• Biomet Faces $10M Retaliation Suit Over Alleged Kickbacks
• Perrigo Aims To Thwart 'Terrible' Mylan Deal With $2B Buyback
• Wyeth Should Face Drug Rebate Claims In Court, States Say
• FDA Approved 'Sham' Label For Cancer Drug, DC Circ. Told
• Why More Businesses Are Considering The B Corp. Model
• Bayer Tells 8th Circ. It Doesn't Owe $9M Fees In GMO Suit
• Don't Forget Child Sites Under The 340B Omnibus Guidance
• 8 Regulatory Considerations For Digital Health Care Cos.
• 1st Circ. Won't Ask Mass. High Court For Help In VisionAid Suit
• Daiichi, Mylan Push High Court To Hear Apotex Drug IP Fight
• Sperm Bank Defeats Negligence Suit Over Ex-Felon's Sample
• Valeant Sent Reeling By Phantom-Sales Allegations
• J&J Unit Can't Escape Idaho Woman's Vaginal Mesh Suit
• Trial Will Be About Fake Drugs, Not Homeopathy, Class Says
• 23andMe Reintroduces DNA Health Test With FDA Blessing
• An Update On Section 101 Rejection Rates At The USPTO
• FDA Expresses Safety Concerns Over AstraZeneca Gout Drug
• P&G Urges Stay Of Probiotic Class For High Court Review
• Apotex Sets Stage For Next Fed. Circ. BPCIA Dispute
• 4 Reasons To Use Electronic Deposition Exhibits
• Payroll Tax Breaks Save San Francisco Cos. $44M: Report
• Medtronic Cleared Of NuVasive Design Patent Claim
• Allergan Can't Escape Botox Antitrust Suit
• GCs Brace For Shift In State AGs Priorities
• Goodwin Procter Nabs Tech Pro For Silicon Valley Office
• US Government Hit With Suit Over Vaccine Contract Payment
• Sequenom's 'Sky Is Falling' Claims Blasted In DNA Patent Row
• Health Care Firm Hall Render Opens Seattle-Area Office
• 4 Things You Should Never Say To An Associate
• Stryker Fights For $8.6M Implant Coverage Win In 6th Circ.
• Merck Must Hand Over Payment, Job Data In Sex Bias Suit
• Sigma-Aldrich Sells Chemicals Biz Amid $17B Merck Takeover
• PTAB Denies Another Kyle Bass Petition For Drug Review
• Cymbalta Claims Too Different For Class Actions, Judge Says
• Otsuka Sues FDA Over Approval Of Abilify Maintena Rival
• Stroke Prevention Co. Gets $57M Injection From Backers
• Pa. Women Gets 2.5 Years For Selling Banned Diet Drugs
• Issues Facing Life Sciences Cos. After EU-US Safe Harbor
• 23andMe Can't Kibosh Classwide Arbitration In False Ad Row
• Purchasers Win Cert. Again In Blood Test Antitrust MDL
• J&J Unit Hit With $5.6M Verdict Over Calif. Risperdal Death
• High Court Cases Could Clear Way For Bigger Patent Damages
• Anda Appeals 'Pill Mill' Coverage Loss to 11th Circ.
• J&J Tells High Court $140M Motrin Label Verdict Can't Stand
• FDA Delays OKing Shire's Eye Drug As Baxalta Bid Dangles
• Biogen Attacks Bass Group's AIA Review Bid For MS Drug
• NC Jury Hands Boston Scientific Win In Pelvic Mesh Case
• Ex-Access CEO Loses Bid For House Arrest In Fraud Case
• Taylor-Wharton Unsecured Creditors Blast 'Warp-Speed' Sale
• Amgen Calls For Halt To Neulasta Biosimilar Marketing
• Fed. Circ. Affirms $4M Trade Secrets Verdict Against Globus
• Perrigo, Mylan Want Retractions In $27B Hostile Bid Fight
• Jurisdiction In Hatch-Waxman Actions Against Foreign Entities
• OPINION: The Bitter Pill Of Competition Within Large Law
• Justices To Review Standard For Willful Patent Infringement
• Propofol Injury Suit Still Must Prove Teva Has Florida Ties
• Adderall Antitrust Class Has Standing Questioned At Trial
• Homeopathic Co. Says Buyers Bear Burden At Upcoming Trial
• FDA Holds Off Approval Of AstraZeneca Diabetes Treatment
• 4 Questions After Amgen-Sandoz Rehearing Bids Fizzle Out
• Perrigo Ex-Worker Pushes Back On Nixed FCA Drug Claims
• FDA Removes Pacira Warning Letter Amid Free Speech Suit
• J&J Wins First Tylenol Liver Damage Trial
• Former Boston Scientific Atty Joins Baker Sterchi
• PTAB Again Rejects Kyle Bass AIA Review Bid Of Drug Patent
• Is A Medical Device Cyber Vulnerability A Design Defect?
• Calif. Medical Pot Shops Fight IRS Write-Off Bans
• Feds Slam Ex-Access CEO's Bid For 6-Months House Arrest
• Momenta, Sandoz Sought Clot Drug Monopoly, Suit Says
• Fed. Circ. Won't Rehear Amgen-Sandoz Biosimilar Dispute
• TriReme Fears Bankruptcy After $20M Catheter Row Loss
• Ferring's Muted Fertility Drug Recall Falls Within FDA Rules
• 4 Issues To Watch After 340B Orphan Drug Ruling
• Suits Alleging Ethicon Device Spreads Cancer Consolidated
• Endo Lobbies For Dismissal Of Painkiller Pay-For-Delay Suit
• NexGen Patient Presses Zimmer In 1st MDL Test Trial
• Otsuka Loses Fee Bid In Abilify Patent Suit
• J&J's Marketing Of Risperdal For Children Slammed In Trial
• Ex-Access CEO Asks For House Arrest To See Kids Graduate
• Sen. Turns Up Heat As WTO Discusses Drug Patent Waiver
• Drugmaker Wants 12 Firms Booted From Pay-For-Delay MDL
• Metadata 101 For Lawyers: A 2-Minute Primer
• Valeant Says Feds Probing Its Financial Assistance Program
• Teva's $512M Provigil Deal Looks Good To Judge
• Exeltis Sues Acella Over Alleged Drug Trade Secrets Theft
• Homeopathic Co. Says False Ad Suit Lacks Evidence
• 3rd Circ. To Hear Appeal Of Cert. In Provigil Antitrust Row
• 340B Orphan Drug Discounts Dialed Back
• Consumers Pulling A Fast One In Cymbalta Case, Eli Lilly Says
• Avon Buyers Take Class Bid In False Ad Suit To 2nd Circ.
• Taro Infringed Schizophrenia Drug Patents, Suit Claims
• Amgen Can't Enforce Biosimilar Law, Hospira Says
• Bayer Says Woman's Mirena Claims Are Time-Barred
• Ex-Gov. McDonnell Takes Bribery Fight To High Court
• Ex-Access CEO Gets 3.5 Years For Fraud, Tax Evasion
• Hospira To Pay $400K Back Wages In Hiring Bias Case
• Body Part Snatching Case Should Go To Trial, Relatives Say
• NY AG Opens Antitrust Inquiry Into Turing Drug Practices
• Supplement Co. Wants FTC Attys Booted From Labeling Suit
• Insurer Refuses To Cover Workout Supplement Injury Suits
• GSK Says FDA Orders Nix Reed Smith Atty's Widow's Claims
• High Court Denies Hollister Ex-Beneficiaries' ERISA Appeal
• JPML Consolidates Birth Defect Suits Over GSK's Zofran
• Cryogenics Co. Gets Interim Approval To Tap $14M DIP
• FDA Warning Wire: Bird Poop, Ebola, Hello Kitty
• Dozens Of Pelvic Mesh Suits To Join J&J MDL In W.Va.
• Food Safety Co. Knew Of Problems Before IPO, Investors Say
• FDA Stalls On Collegium's 'Abuse-Deterrent' Painkiller
• Wal-Mart, Others Blast FCA Suit Alleging They Sold Old Meds
• Enzo Reaches $10M Deal With Affymetrix To End Patent Row
• CORRECTED: Helsinn, Dr. Reddy's Settle Patent Suit Over Generic Aloxi
• Epstein Becker Grabs SAIC, Miller Canfield Technology Pros
• Nutraceutical Wants Proposed 'Sugar Pill' Class Action Nixed
• Bristol-Myers Settlement: A Strong Warning To Joint Venturers
• Calif. OKs Nation's Toughest Limits On Livestock Antibiotics
• Eli Lilly Beats 2nd Consolidation Bid In Cymbalta Litigation
• Roche Pays $580M For Biotech Developing Arthritis Treatment
• UK Watchdog Puts Conditions On Reckitt, K-Y Deal
• Inovio Beats Former Pharma Exec's Stock Options Suit
• Hi-Tech Fights $35M FTC Contempt Motion in Supplement Suit
• WikiLeaks Releases Secret Text Of TPP's IP Section
• Helsinn, Roche Sue Over Planned Generic Of Nausea Drug
• FDA's Abilify Smack-Down Boosts Imitator Drugs
• 10 Ways To Become A 360-Degree Lawyer
• $100M Boston Scientific Mesh Verdict Slashed To $10M
• Obama's FDA Nominee Too Close To Big Pharma: Sanders
• Drug Antitrust Issues With Daraprim And Beyond
• Pa. Hospital Urges Class Cert. In Med Supply Antitrust Row
• Phishing For Coverage: When Is Fraud A 'Computer Fraud'?
• Impossibility Preemption Is Possible In 510(k) Device Cases
• Watchdog Verifies FDA Review Of Disputed Device Approvals
• Pfizer Beats Zoloft Birth Defect Suit In Philadelphia
• Reed Smith Atty's Widow Fights GSK's Bid To Nix Suicide Suit
• Ex-Access CEO Deserves 4 Years For Fraud, Feds Say
• Takeda Strikes Possible Deal, Halts Nev. Actos Cancer Trial
• Biotech CEO Backpedals On Guilty Plea For Funneling Shares
• Amicus Faces Shareholder Suit Over Rosy NDA Statements
• Sheller To Appeal Suit Over FDA Inaction On Risperdal Docs
• Price Hike Scrutiny May Land Drug Cos. In Antitrust Hot Water
• Hedge Fund Group Gets Review Of Bowel Disease Drug Patent
• Supplements Falsely Marketed As Steroids, Suit Says
• Cytomx Prices IPO Below Range As More Biotechs Scale Down
• Taylor-Wharton Ch. 11 Auction Proposal Put On Fast Track
• Finance Chairman Bristles At TPP's Drug, Tobacco Provisions
• The Retrospective Approach To Companion Diagnostics
• Colo. Pot Credit Union Says No Trial Needed In KC Fed Case
• Blackstone Inks $8B Deal For Health Care REIT
• GSK Rips 'Junk Science' By Reed Smith Atty Widow's Expert
• Celgene Trying To Skirt $700M In FCA Claims, Relator Says
• J&J Says It's Being Harassed During Mesh MDL Discovery
• Hausfeld, Others To Helm Contact Lens Antitrust MDL
• Novartis Ducks Zometa Failure-To-Warn Suit
• Jury Verdict Sinks False Ad Class, Hyland's Tells Judge
• Amazon, GNC, Others Sued Over Workout Supplements
• Wyeth, Abbott Agree To Dismiss Suit Over Stent Patents
• Colo. Judge Tosses 'Convoluted' Genzyme Class Action
• SIGA Asks Del. Justices To Ax $195M PharmAthene Ruling
• FDA Launches Crackdown On Allergy Treatments Labeling
• FTC Steris-Synergy Merger Challenge Halted After Court Loss
• PharMerica Inks $9M FCA Deal Over Kickback Allegations
• FINRA Bans Firm, CEO Over Cancer Drug Kickback Scheme
• Zimmer Rips Bellwether Delays In Knee Implant MDL
• Fox Rothschild Adds Pharma Compliance Pro To NJ Office
• Some Useful Insights From Steris-Synergy Merger Case
• Celgene Can't Limit Claims In FCA Off-Label Marketing Row
• FDA Warning Wire: Salsa, Concussion Relief, Drugged-Up Cow
• MedTel24 In Contempt Of Heart Monitor Patent Order
• Calif. Woman Sues Biomet Claiming Hip Replacement Defects
• 5th Circ. Shouldn't Rehear Toe Implant Fight, Patient Says
• GSK, Teva To Take Lamictal Pay-For-Delay Case To High Court
• Hi-Tech Asks Judge For Recusal Over Seeing Privileged Docs
• Apotex Accuses Amgen Of Sham Patent Litigation
• J&J Win In Children's Motrin Suit Offers New Trial Tactic
• 5 Things Clients Never Tell Their Lawyers
• Allergan Beats Miotox's $600M Botox Royalty Claims
• Cutoff Date Set For Collective Notice In $100M Sex-Bias Suit
• Prograf Class Cert. Makes Case Unworkable, 1st Circ. Hears
• Texas Court Won't Revisit $2M Drug License Arbitral Award
• TPP Compromises Set Stage For Political Standoff
• Nexium Buyers Get $8M Fees In Pay-For-Delay Settlement
• Engaged Capital Protests $857.8M HeartWare-Valtech Deal
• Supreme Court Rejects $1B Gore Patent Suit
• J&J Wins 1st Trial Over Prosima Pelvic Mesh
• AbbVie Docs Not Privileged In Pay-For-Delay Suit, FTC Says
• Bristol-Myers Squibb Pays $14M Over Alleged China Bribes
• 7th Circ. Stands Out On Ascertainability Of Class Actions
• Acacia Unit Settles Medical Patent Suits With CR Bard
• Abbott, Plaintiffs Limit Expert Testimony In Depakote Trial
• Boston Scientific Ducks Pacemaker Defect Suit Under Riegel
• Reckitt Loses Reconsideration Bid In Mucinex Antitrust Row
• Fed. Circ. Says Sandoz Didn't Infringe Cancer Drug Patent
• Midmarket IPO Activity Drops In Q3 But Offers Sizes Grow
• Pfizer Gets Plaintiffs' Expert Blocked In Zoloft Trial
• Jury Asked To Award $9.5M Damages In J&J Pelvic Mesh Case
• Insurer Refuses Coverage For USPlabs In Diet Pill Suits
• FTC's False Ad Claims Against Bayer Baseless, Judge Says
• Amgen Gets Failure-To-Warn Claims Axed From Enbrel Suit
• Sandoz Files Application For Biosimilar To Amgen's Enbrel
• Proskauer-Led NovoCure Raises $165M In Downgraded IPO
• The Minefield Of E-Cigarette Labeling And Promotion
• Ethicon Plaintiffs' Attys Grilled On MDL Consolidation
• GSK Must Face Paxil Liability Suit
• FTC Ending Court Bid To Block $1.9B Steris-Synergy Deal
• Mylan Infringed Cumberland's Acetadote Patent, Judge Rules
• Paul Weiss Must Pony Up Privileged Docs On Defunct Med Co.
• Eisai Loses Bid For Longer Exclusivity In FDA Delay Fight
• Judge Clears Boston Scientific In $200M Stent Patent Case
• 5th Circ. Lets Supplement Maker Sue Texas AG In Label Row
• FTC Pushes 3rd Circ. To Revive Doryx Product-Hopping Case
• Specialty Pharmacy Market Ripe For Private Equity Buyers
• Valeant Hits Apotex With Patent Suit Over Colitis Drug
• Pa. Court Won't Revive $20M Suit Over Skin Drug Patents
• Jones Day Adds Ex-K&L Gates Partner To Pittsburgh Office
• SEC Gets $7M Judgment In Pharma Pump-And-Dump Scheme
• Teva Boosts Presence In Mexico With $2.3B Rimsa Buy
• How Fed. Circ. Views Obviousness-Type Double-Patenting